Beijing Foyou Pharma (601089.SH): Sodium diclofenac enteric-coated capsules received drug registration certificate.

Beijing Foyou Pharma (601089.SH) announced that recently, the company has received the "Drug Registration Certificate" (Certificate Number: 2026S00694) for the production approval of the Enteric-coated Capsules of Diclofenac Sodium Sustained-Release (specification: 75mg) from the National Medical Products Administration ("NMPA"). It is reported that the Enteric-coated Capsules of Diclofenac Sodium Sustained-Release, developed by Aenova, was approved for market in Germany in August 1984. In December 1997, it was approved by the NMPA for domestic market in China at a dosage of 75mg, and in April 2024, it was approved for domestic market at a dosage of 100mg. This drug is used to treat acute inflammation of the joints, gout attacks, chronic joint inflammation, rheumatoid arthritis, ankylosing spondylitis and other inflammatory rheumatic diseases of the spine, pain related to degenerative diseases of the joints and spine, soft tissue rheumatism, post-traumatic or postoperative swelling, pain or inflammation, treatment of dysmenorrhea, and postoperative pain and inflammation caused by orthopedic, dental surgery, or other minor surgical procedures.